The Panova 3 trial proved TTFields' benefit with a gemcitabine-based chemotherapy. However, with up to 50% of patients receiving the FOLFIRINOX regimen, it is unknown if TTFields provide the same survival benefit when combined with this common alternative, representing a critical evidence gap for clinicians.
While approved for locally advanced pancreatic cancer, experts are already questioning its potential in broader applications. Future research could explore using TTFields for low-volume metastatic disease or in older patients unfit for surgery, suggesting the current approval may be a starting point for expanded use.
The mechanism of Tumor-Treating Fields extends beyond direct cell killing. It gently controls cancer by altering the tumor's microenvironment and overall biology to be more favorable. This not only controls tumor growth but can also contribute to symptomatic relief for the patient.